Merck follows Bristol with EU green light for immune cancer drug
May 22, 2015 at 07:22 AM EDT
May 22 (Reuters) - European regulators have recommended approval of Merck & Co Inc's immune system-boosting cancer drug Keytruda, following a similar green light last month for Bristol-Myers Squibb Co's rival product Opdivo.